Klaus Vedfelt Investment Overview Crispr Therapeutics AG (NASDAQ:CRSP), the Zug, Switzerland headquartered biotech that, in partnership with Boston based Pharma giant Vertex (VRTX), secured a first-ever approval for a CRISPR/Cas9 gene editing therapy, Casgevy, directed against Sickle Cell Disease (“SCD”) and transfusion dependent beta thalassemia (“TDT”), announced its Q2 earnings yesterday. No Casgevy Revenue Figures, Plenty of Positive Progress With Casgevy having been approved to treat SCD in Decembe ...